RU2019135690A - Терапевтическое средство для лечения болезни телец леви, содержащее производное пиразолохинолина - Google Patents
Терапевтическое средство для лечения болезни телец леви, содержащее производное пиразолохинолина Download PDFInfo
- Publication number
- RU2019135690A RU2019135690A RU2019135690A RU2019135690A RU2019135690A RU 2019135690 A RU2019135690 A RU 2019135690A RU 2019135690 A RU2019135690 A RU 2019135690A RU 2019135690 A RU2019135690 A RU 2019135690A RU 2019135690 A RU2019135690 A RU 2019135690A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- treatment
- therapeutic agent
- dementia
- body containing
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 3
- 229940124597 therapeutic agent Drugs 0.000 title claims 3
- UXYHZIYEDDINQH-UHFFFAOYSA-N C1=CNC2=C3C=NN=C3C=CC2=C1 Chemical class C1=CNC2=C3C=NN=C3C=CC2=C1 UXYHZIYEDDINQH-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- CKJDCNZBABIEBZ-HNNXBMFYSA-N 7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-[(3S)-oxolan-3-yl]-5H-pyrazolo[4,3-c]quinolin-4-one Chemical compound COC1=NC=C(C)C(C=2C=C3NC(=O)C=4C=NN(C=4C3=CC=2)[C@@H]2COCC2)=C1C CKJDCNZBABIEBZ-HNNXBMFYSA-N 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 201000002832 Lewy body dementia Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000009829 Lewy Body Disease Diseases 0.000 claims 3
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (12)
1. Терапевтическое средство для лечения деменции с тельцами Леви или болезни Паркинсона с деменцией, содержащее (S)–7–(2–метокси–3,5–диметилпиридин–4–ил)–1–(тетрагидрофуран–3–ил)–1H–пиразолo[4,3–c]хинолин–4(5H)–он, представленный формулой (I):
или его фармацевтически приемлемую соль.
2. Способ лечения деменции с тельцами Леви или болезни Паркинсона с деменцией, включающий введение (S)–7–(2–метокси–3,5–диметилпиридин–4–ил)–1–(тетрагидрофуран–3–ил)–1H–пиразолo[4,3–c]хинолин–4(5H)–она, представленного формулой (I):
или его фармацевтически приемлемой соли пациенту, нуждающемуся в этом.
3. (S)–7–(2–Метокси–3,5–диметилпиридин–4–ил)–1–(тетрагидрофуран–3–ил)–1H–пиразолo[4,3–c]хинолин–4(5H)–он, представленный формулой (I):
или его фармацевтически приемлемая соль для применения в лечении деменции с тельцами Леви или болезни Паркинсона с деменцией.
4. Применение (S)–7–(2–метокси–3,5–диметилпиридин–4–ил)–1–(тетрагидрофуран–3–ил)–1H–пиразолo[4,3–c]хинолин–4(5H)–она, представленного формулой (I):
или его фармацевтически приемлемой соли для изготовления терапевтического средства для лечения деменции с тельцами Леви или болезни Паркинсона с деменцией.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513727P | 2017-06-01 | 2017-06-01 | |
| US62/513,727 | 2017-06-01 | ||
| PCT/JP2018/020650 WO2018221551A1 (ja) | 2017-06-01 | 2018-05-30 | ピラゾロキノリン誘導体を含有するレビー小体病治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019135690A true RU2019135690A (ru) | 2021-07-13 |
| RU2019135690A3 RU2019135690A3 (ru) | 2021-08-25 |
| RU2802212C2 RU2802212C2 (ru) | 2023-08-23 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| ES2961554T3 (es) | 2024-03-12 |
| AU2018278422B2 (en) | 2022-03-17 |
| MX2019013397A (es) | 2020-02-07 |
| EP3632438A4 (en) | 2020-12-23 |
| IL270357B2 (en) | 2024-02-01 |
| IL270357B1 (en) | 2023-10-01 |
| TWI784006B (zh) | 2022-11-21 |
| EP3632438A1 (en) | 2020-04-08 |
| TW201902479A (zh) | 2019-01-16 |
| IL270357A (ru) | 2020-02-27 |
| RU2019135690A3 (ru) | 2021-08-25 |
| US20200155541A1 (en) | 2020-05-21 |
| CN110612102A (zh) | 2019-12-24 |
| CA3061884A1 (en) | 2019-10-29 |
| BR112019023552A2 (pt) | 2020-06-02 |
| EP3632438B1 (en) | 2023-08-23 |
| US11311530B2 (en) | 2022-04-26 |
| WO2018221551A1 (ja) | 2018-12-06 |
| KR20200010220A (ko) | 2020-01-30 |
| AU2018278422A1 (en) | 2019-11-21 |
| JPWO2018221551A1 (ja) | 2020-04-02 |
| JP7269875B2 (ja) | 2023-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA520411325B1 (ar) | مشتقات 3-(1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6-دايون واستخداماتها | |
| EA201991693A1 (ru) | Производное пиридина в качестве ингибитора ask1 и способ его получения и применения | |
| WO2016205475A3 (en) | Tgr5 modulators and methods of use thereof | |
| PH12018500437A1 (en) | Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof | |
| MX2018003215A (es) | Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2. | |
| PH12016502168B1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| WO2017062468A8 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| WO2015042078A8 (en) | Substituted aminopyrimidine compounds and methods of use | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| PH12017500479A1 (en) | Liquid inhalation formulation comprising prl554 | |
| CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
| SG10201803862UA (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
| HRP20202051T1 (hr) | Aril supstituirani pirimidini za uporabu kod infekcije virusom influence | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| MX2018003186A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[ 4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer. | |
| PH12016501651B1 (en) | Triazine compound and use thereof for medical purposes | |
| WO2017090039A3 (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
| TN2019000204A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| WO2016089060A3 (en) | Heterocyclic derivatives and use thereof | |
| WO2016126085A3 (ko) | 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물 | |
| GEP20207128B (en) | Aminothiazole derivatives useful as antiviral agents | |
| WO2016011049A3 (en) | Compositions and methods for disease treatment using nanoparticle delivered compounds | |
| TR201904514T4 (tr) | Makrosiklik LRRK2 kinaz inhibitörleri. | |
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
| WO2016199076A3 (en) | Polymorphic forms of afatinib free base and afatinib dimaleate |